How does Jeff Galvin, CEO of Addimmune, THINK?
Jeff Galvin Is Taking a New Approach to Medicine There’s a revolution brewing in medicine, and the paradigm-shifting innovations in the gene and cell therapy space are right at the heart of the movement. Jeff Galvin, CEO of American Gene Technologies® (AGT ™) and Addimmune™, has seen firsthand what gene and cell therapies can do. With a background…
Read MoreWhy Is It So Difficult to Find an HIV Cure?
The silent HIV epidemic has been ongoing for 4 decades. AIDS-related illnesses have claimed over 32 million lives since the beginning of the HIV epidemic in 1981. The death toll, societal impact, and economic effects of the HIV epidemic have made HIV/AIDS one of the greatest public health threats the world has ever known. Governments,…
Read MoreHIV Has Been Cured For a 5th Time, Now Researchers Are Developing Scalable Methods
Contributing Author Luke Williams, Sales and Marketing A mounting body of evidence shows that HIV, once thought to be an incurable lifelong condition, is indeed curable. The “Dusseldorf Patient” made headlines recently when a stem cell transplant to treat life-threatening cancer also cured him of HIV. However, the transplantation method is incredibly dangerous and the…
Read MoreThe Biotech Project Podcast Dives into the Passionate Vision of Jeff Galvin
The Biotech Project podcast hosts Scott J Resnik, MBA, NYS EMT-CC, and John Walsh, MD, sit down with American Gene Technologies® founder and CEO Jeff Galvin for a lively and inspiring discussion.Watch the full episode to follow Jeff’s journey as he builds a company that’s on a path toward revolutionizing the traditional approach to treating…
Read MoreAmerican Gene Technologies Celebrates Another Year of Progress
Contributing Author John Vandermosten, Senior Biotechnology Analyst In 2022, the world was collectively compelled to endure a surge in viral outbreaks, the horror of the Russia-Ukraine war and rampant inflation, which has led many to a state of pessimism. But, the dramatic events of 2022 have overshadowed other, more reassuring news. In contrast to the gloom…
Read MorePhase 1 HIV Clinical Trial Data Published in “Frontiers in Medicine” Journal
Contributing Author Luke Williams, Sales and Marketing American Gene Technologies® (AGT) designed AGT103-T in hopes of functionally curing HIV. The therapeutic is made of the patient’s own T cells which have been enhanced for HIV resistance, and data from the Phase 1 human trial has recently been published in the journal Frontiers in Medicine. HIV…
Read MoreGene Therapy Clinical Trial Requirements
Contributing Author John Vandermosten, Senior Biotechnology Analyst Gene Therapy Does It “My Way” In 1990, gene therapy burst onto the world stage with the first clinical trial aimed at a genetic disease. This effort, led by a team at the National Institute of Health, successfully treated a four-year-old girl with severe combined immunodeficiency (SCID), more commonly…
Read MoreShareTreck Host Interviews Jeff Galvin on The Future of Medicine
Raj Natarajan, host of ShareTreck, goes behind the scenes with Jeff Galvin, Founder and CEO of American Gene™ in this compelling interview learn how gene therapy works, and what it means for people with deadly diseases, as well as how it will impact the current pharmaceutical landscape. The company is currently in the midst of…
Read MoreThe Future of Gene Therapy
Contributing Author John Vandermosten, Senior Biotechnology Analyst Economies of scale can apply to gene therapy too Gene therapy’s advantage is its ability to modify the genetic cause of disease. The approach has the potential to correct genetic errors, cure genetic disease and fight serious infections using the body’s own machinery. Its capabilities seem almost limitless, as…
Read MoreFDA Gene Therapy Approvals
Contributing Author John Vandermosten, Senior Biotechnology Analyst Despite the impact of the pandemic and the seemingly solitary focus of the health care machine on addressing SARS-CoV-2, the gene therapy space continued to progress over the last 18 months. Several new approvals were granted and promising candidates were advanced in clinical trials and submitted to regulatory authorities. …
Read MoreHIV Breakthrough at American Gene Technologies Gets Researchers Closer to the Cure
Subscribe to our YouTube Channel In May 2021, American Gene Technologies (AGT), a clinical-stage biotechnology company, announced the treatment of the first participant in its Phase I clinical trial to evaluate the safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore Potent Antiviral Immune Responses, NCT04561258), participants are infused…
Read MoreHIV Cure Program Clinical Trial Update – Spring 2021
Subscribe to our YouTube Channel This April 2021, Kelly Huang, Ph.D., Sommar Nettles, M.Sc., and Anisha Mannan, M.Sc. from American Gene Technologies’ AGT103-T product team share clinical trial updates from Phase 1 of the drug product’s clinical trials for the HIV Cure Program. So far, 6 participants have been enrolled in the drug study at…
Read More